$2.58T
Total marketcap
$174.33B
Total volume
BTC 50.03%     ETH 15.87%
Dominance

Ionis Pharmaceuticals IONS Stock

42.03 USD {{ price }} -1.222093% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
6.13B USD
LOW - HIGH [24H]
41.97 - 42.78 USD
VOLUME [24H]
853.93K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.56 USD

Ionis Pharmaceuticals Price Chart

Ionis Pharmaceuticals IONS Financial and Trading Overview

Ionis Pharmaceuticals stock price 42.03 USD
Previous Close 40.82 USD
Open 40.81 USD
Bid 0 USD x 800
Ask 0 USD x 1000
Day's Range 40.6 - 41.78 USD
52 Week Range 32.69 - 48.82 USD
Volume 1.22M USD
Avg. Volume 1.22M USD
Market Cap 5.97B USD
Beta (5Y Monthly) 0.523591
PE Ratio (TTM) N/A
EPS (TTM) -2.56 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 48.58 USD

IONS Valuation Measures

Enterprise Value 4.85B USD
Trailing P/E N/A
Forward P/E -12.334319
PEG Ratio (5 yr expected) 0.22
Price/Sales (ttm) 10.357285
Price/Book (mrq) 12.254556
Enterprise Value/Revenue 8.417
Enterprise Value/EBITDA -10.794

Trading Information

Ionis Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.523591
52-Week Change 18.23%
S&P500 52-Week Change 20.43%
52 Week High 48.82 USD
52 Week Low 32.69 USD
50-Day Moving Average 38.12 USD
200-Day Moving Average 39.91 USD

IONS Share Statistics

Avg. Volume (3 month) 1.22M USD
Avg. Daily Volume (10-Days) 2.1M USD
Shares Outstanding 143.09M
Float 142.04M
Short Ratio 5.71
% Held by Insiders 0.73%
% Held by Institutions 93.22%
Shares Short 6.52M
Short % of Float 5.40%
Short % of Shares Outstanding 4.56%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -57.099%
Operating Margin (ttm) -80.69%
Gross Margin -46.34%
EBITDA Margin -77.98%

Management Effectiveness

Return on Assets (ttm) -10.75%
Return on Equity (ttm) -54.99%

Income Statement

Revenue (ttm) 575.97M USD
Revenue Per Share (ttm) 4.05 USD
Quarterly Revenue Growth (yoy) -8.00000000000000000000000000000000%
Gross Profit (ttm) -257866000 USD
EBITDA -449144000 USD
Net Income Avi to Common (ttm) -328880000 USD
Diluted EPS (ttm) -2.25
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.35B USD
Total Cash Per Share (mrq) 16.45 USD
Total Debt (mrq) 1.36B USD
Total Debt/Equity (mrq) 279.79 USD
Current Ratio (mrq) 9.809
Book Value Per Share (mrq) 3.402

Cash Flow Statement

Operating Cash Flow (ttm) -376712000 USD
Levered Free Cash Flow (ttm) -180147008 USD

Profile of Ionis Pharmaceuticals

Country United States
State CA
City Carlsbad
Address 2855 Gazelle Court
ZIP 92010
Phone 760 931 9200
Website https://www.ionispharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 796

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

Q&A For Ionis Pharmaceuticals Stock

What is a current IONS stock price?

Ionis Pharmaceuticals IONS stock price today per share is 42.03 USD.

How to purchase Ionis Pharmaceuticals stock?

You can buy IONS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Ionis Pharmaceuticals?

The stock symbol or ticker of Ionis Pharmaceuticals is IONS.

Which industry does the Ionis Pharmaceuticals company belong to?

The Ionis Pharmaceuticals industry is Biotechnology.

How many shares does Ionis Pharmaceuticals have in circulation?

The max supply of Ionis Pharmaceuticals shares is 145.75M.

What is Ionis Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Ionis Pharmaceuticals PE Ratio is now.

What was Ionis Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Ionis Pharmaceuticals EPS is -2.56 USD over the trailing 12 months.

Which sector does the Ionis Pharmaceuticals company belong to?

The Ionis Pharmaceuticals sector is Healthcare.

Ionis Pharmaceuticals IONS included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Dow Jones U.S. Biotechnology In DJUSBT 2844.59 USD
+0.08
79.29M USD 2839.63 USD 2860.51 USD 79.29M USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD